Jenny Bailey Cooper, PhD profile page

Dr. Jenny Bailey Cooper has spent her career to date working in the field of gut health. She has a PhD in gastrointestinal immunology from the University of Bristol and 18 years of research experience in gastrointestinal disease. Bailey Cooper has a keen interest in intestinal inflammation, particularly mucosal barrier function and novel therapeutics to disrupt inflammatory pathways. In 2019 Bailey Cooper became co-founder and chief executive officer of Ferryx. Ferryx develops next-generation probiotics to improve gut health. She has been responsible for the development of Ferryx's proprietary products since their early stages and has led commercialization over the last five years. Bailey Cooper has led Ferryx through investment rounds, successful grant funding and into revenue generation via the launch of Ferryx's first product, Ferrocalm^TM, in December 2022.